Alexion adds fourth indication for C5 inhibitor Ultomiris in rare autoimmune disorder
AstraZeneca’s rare disease arm Alexion scored its fourth approval for Ultomiris in a rare autoimmune disorder after Phase 3 data showed …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
